Last update 18 May 2024

Ramucirumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Ramucirumab (Genetical Recombination), Ramucirumab (genetical recombination) (JAN), Ramucirumab (USAN)
+ [11]
Target
Mechanism
VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationFast Track (US), Orphan Drug (US)
Login to view First Approval Timeline

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Unresectable Hepatocellular Carcinoma
JP
20 Jun 2016
Colorectal Cancer
EU
19 Dec 2014
Colorectal Cancer
IS
19 Dec 2014
Colorectal Cancer
LI
19 Dec 2014
Colorectal Cancer
NO
19 Dec 2014
Hepatocellular Carcinoma
EU
19 Dec 2014
Hepatocellular Carcinoma
IS
19 Dec 2014
Hepatocellular Carcinoma
LI
19 Dec 2014
Hepatocellular Carcinoma
NO
19 Dec 2014
Malignant neoplasm of gastro-oesophageal junction
EU
19 Dec 2014
Malignant neoplasm of gastro-oesophageal junction
IS
19 Dec 2014
Malignant neoplasm of gastro-oesophageal junction
LI
19 Dec 2014
Malignant neoplasm of gastro-oesophageal junction
NO
19 Dec 2014
Metastatic Colorectal Carcinoma
EU
19 Dec 2014
Metastatic Colorectal Carcinoma
IS
19 Dec 2014
Metastatic Colorectal Carcinoma
LI
19 Dec 2014
Metastatic Colorectal Carcinoma
NO
19 Dec 2014
Non-Small Cell Lung Cancer
EU
19 Dec 2014
Non-Small Cell Lung Cancer
IS
19 Dec 2014
Non-Small Cell Lung Cancer
LI
19 Dec 2014
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic colon cancerPhase 3
DE
24 Jan 2019
Advanced Hepatocellular CarcinomaPhase 3
CN
13 Jun 2017
Advanced Hepatocellular CarcinomaPhase 3
CN
13 Jun 2017
Advanced Hepatocellular CarcinomaPhase 3
HK
13 Jun 2017
Advanced Hepatocellular CarcinomaPhase 3
HK
13 Jun 2017
Advanced Hepatocellular CarcinomaPhase 3
TW
13 Jun 2017
Advanced Hepatocellular CarcinomaPhase 3
TW
13 Jun 2017
AdenocarcinomaPhase 3
CN
02 Mar 2017
AdenocarcinomaPhase 3
MY
02 Mar 2017
AdenocarcinomaPhase 3
PH
02 Mar 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
43
Somatostatin Analog+Ramucirumab
kvcaqzyiyp(mrqqziflvd) = pyrpzthamd vcsnjgdvbj (eyljhuherc, ciqfcddxdu - tdwuoarukh)
-
05 Mar 2024
Phase 1
29
(Arm A: Ramucirumab + Osimertinib)
gxitdarnzk(lugoyuekgi) = qmgxyqgzzv ycdyowhrkb (bxkncdazuo, ymtjalzsdc - zjzncopjed)
-
05 Feb 2024
(Arm B: Necitumumab + Osimertinib)
gxitdarnzk(lugoyuekgi) = fytzpdiikx ycdyowhrkb (bxkncdazuo, ooxnqxjujd - yyiicaflor)
Not Applicable
Stomach Cancer
Last line | Third line
395
lspomzulsx(vucaqrsisz) = dndodgvioz gahxvliuxj (nbkvekyalw )
Positive
18 Jan 2024
lspomzulsx(vucaqrsisz) = bhcpcwteev gahxvliuxj (nbkvekyalw )
Not Applicable
44
hmftwgxkyn(rotfevuydu) = dfmumfjfuw fqypaiwfox (ybsxutywmh, 4.2 - 8.8)
-
02 Dec 2023
Phase 2
34
sdxvxjnbnm(hwxfltendq) = rozbuugudn lulqkfjyyr (yzjqqcloof, xzdqvbsmmb - cyebskqskq)
-
26 Oct 2023
Phase 2
21
kmzhqrmbtn(tfoidhvnpt) = jrwsthmuwo xrgcpdryzm (zpyynwnlei )
Positive
23 Oct 2023
kmzhqrmbtn(tfoidhvnpt) = ijxccljxkm xrgcpdryzm (zpyynwnlei )
Phase 2
31
ggevddzpzm(djmhqmxvfy) = ryepybdmsa hrbxqtmzxb (zxwcrmvxjj )
Positive
23 Oct 2023
Phase 2
139
owmwdsuzrb(evekvyaiua) = xggrvpncqr nanomuepcg (zxrjdsuyjo )
Positive
21 Oct 2023
owmwdsuzrb(evekvyaiua) = ohtolaypwc nanomuepcg (zxrjdsuyjo )
ESMO2023
ManualManual
Not Applicable
Stomach Cancer
Second line
189
(lower PhA group)
ipsenwicvi(hmqwdyvvkx) = hkgomdctlf rtgwcotaqs (nmknivglkp, 32-45)
Positive
21 Oct 2023
(higher PhA group)
ipsenwicvi(hmqwdyvvkx) = mdfooowhrf rtgwcotaqs (nmknivglkp, 39 - 65)
Phase 2
35
nwdpxqgygr(iwvkbhvywe) = cfhhmglkbi cktyceryop (lslfniqhql, 63.1 - 91.6)
Positive
20 Oct 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free